ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech

Terry Chrisomalis
Investing Group Leader
(15min)

Summary

  • ORIC Pharmaceuticals is advancing ORIC-114 for 1st-line EGFR/HER2 exon 20 NSCLC, with comprehensive data expected in the 2nd half of 2025 and a phase 3 trial to start in 2026.
  • ORIC-944 in combination with ERLEADA and/or NUBEQ is being tested for the treatment of patients with metastatic castration-resistant prostate cancer; Data readouts from dose-optimization cohorts expected in 2025.
  • The global prostate cancer market is expected to reach $29.2 billion by 2035; Approximately between 10% to 20% of all prostate cancers are as classified as castration-resistant.
  • The company expects to have 7 data readouts in the next 18 months, presenting multiple catalysts for investors to look forward to.
  • Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More »
Indian Lab Technician Analyzes Samples

sanjeri

The last time I wrote an article on ORIC Pharmaceuticals (NASDAQ:ORIC) it was with respect to a Seeking Alpha article entitled "ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value". In this article, I

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.42K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About ORIC Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on ORIC

Related Stocks

SymbolLast Price% Chg
ORIC
--
Compare

Trending Analysis

Trending News